Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06332443
Other study ID # CER-CEMTL-2023-3086
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2023
Est. completion date March 15, 2026

Study information

Verified date March 2024
Source Maisonneuve-Rosemont Hospital
Contact Serge Marquis, inf
Phone 514-252-3400
Email smarquis.hmr@ssss.gouv.qc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To our knowledge, no study has compared the difference between these two NA techniques. Early postoperative adverse events like uncontrolled pain, orthostatic hypotension, urinary retention, and prolonged motor block are linked to late patient mobilization, prolong hospitalization and failure to discharge in outpatient setting. The type of anesthesia used may have an important impact. Therefore, this study has the potential to improve the already established ERAS program and improve patients care perioperative and postoperative. Showing that SED-EA and SA are equivalent will allow for a more efficient and reliable technique for THA/TKA ERAS program that can be further translated into other lower limb surgeries.


Description:

Primary objective is to compare the overall complication rate within 72 hours after surgery, categorized according to the Clavien-Dindo classification (15), between both techniques following THA and TKA surgery. Secondary objectives are to compare the following perioperative and postoperative events between both groups: 1. Perioperative 1. Preoperative pain levels and opioid/analgesics consumption 2. Time needed to perform the technique (from the first handling the needle to sterile drapes removal from the back of the patient) 3. Time needed for the SA or SED-EA to achieve adequate sensory block (from LA injection to the absence of cold feeling at T8 allowing surgical incision 4. Intraoperative blood loss 5. Need for dose adjustment intraoperatively 6. Hemodynamic instability defined by hypotension (-20% from basal values prior to entering the OR, at the time of the consent). 2. Post-operative 1. Time to motor and sensory function return 2. Time to mobilization 3. Pain evaluated with Visual analog scale immediately after surgery and up to 72 hours after surgery 4. Opioid consumption up to 48 hours 5. Hospital LOS and incidence of failed discharge at planned time 6. Complications related to the technique performed (Post-dural puncture headache, local infection, hematoma etc.) HYPOTHESIS We hypothesize that the incidence of the overall complication rate within 3 days after surgery, categorized according to the Clavien-Dindo classification will be equivalent between both groups; SED-EA and SA.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date March 15, 2026
Est. primary completion date March 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patient has symptomatic hip or knee OA requiring primary joint replacement (not associated with unusual treatments such as bone graft, concomitant osteotomy, revision implant, etc.). - Patient who is candidate for our ERAS program - Patient understands the study condition - Patient capable of giving informed consent. - Someone to accompany the patient to the Pre-admission Clinic and hospital the day of the surgery and to be available in the first postoperative week during home recovery. Exclusion Criteria: - Patients with contraindication to NA (spinal anatomical abnormalities, coagulation disorders, infection at the puncture site) - Allergy to LAs used in the study - Unable to communicate with the investigators, unable to read the questionnaire, unable to keep track and notes of the medication taken at home - Lack of home services offered by the local community service centre in the area. - BMI > 40. - Psychiatric disease limiting participation or interfering with the ability to provide consent or assessment - Need for long-term urinary Foley catheter post-op. - Allergies to sulfonamides or other medications specified in the protocol. - Cognitive impairment or communication problem - Pulmonary embolism or deep vein thrombosis in the past year. - Need for long-term anticoagulation therapy. - Current corticotherapy or systemic corticotherapy in the past year (unless confirmation of a cortrosyn test prior to surgery). - Systemic disease involvement (diabetes, heart, kidney, blood, etc.) necessitating special perioperative care (intensive care, multiple transfusions, dialysis, etc.). - Coagulation disorder increasing the risk of intraoperative and postoperative bleeding including thrombocytopenia (platelet count lower than 80), hemophilia, prolonged INR (1,4 and over) and any order coagulation disorder deemed a contra-indication to neuraxial anesthesia.. - Locomotor problem, other than the joint to be replaced, imposing functional limitations that prevent movement without technical or physical assistance. - Neurological or balance disorder. - Living space incompatible with home care. - Clcr < 30 ml/min (Cockcroft-Gault formula). - Pregnancy

Study Design


Intervention

Procedure:
Spinal anesthesia
Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
Sedation epidural anesthesia
Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.

Locations

Country Name City State
Canada Hopital Maisonneuve Rosemont Montreal Quebec

Sponsors (9)

Lead Sponsor Collaborator
Maisonneuve-Rosemont Hospital Ariane Clairoux, Issam Tanoubi, Karina Pellei, Marie-Eve Bélanger, Mina Wahba Morcos, Philippe Richebé, Pierre Drolet, Veronique Brulotte

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events The number of overall adverse events will be categorized according to the Clavien-Dindo classification Day 3
Secondary Time needed by the anesthesiologist to perform the technique Defined as the time frame from the end of the disinfection process to the time the medication is injected in the SA group or the catheter is secure in the SED-EA group (unit: mins). Day 0
Secondary Time needed for the SA or SED-EA to achieve adequate sensory block defined as the time frame from the end of the anesthesia technique to the time the patient can no longer feel cold at her lower extremity. Day 0
Secondary Intraoperative blood loss measured from the contents of suction bottles and the increased weight of surgical swabs by the operative nurse. Day 0
Secondary intraoperative muscle tension rating which is rated on 4-point scale that blinded surgeons will use. The scale is as follows: 0 = most relaxed; 1 = mildly tight; 2 = moderately tight; and 3 = very tight. Day 0
Secondary Extra Lidocaine needed An extra 5 mL of lidocaine 2% will be administrated through the SED-EA catheter if muscle tension or analgesia is judged not optimal by the surgeon and/or anesthesiologist. Need for dose adjustment of the SED-EA intraoperatively will be recorded by the anesthetist. Day 0
Secondary Conversion to GA If muscle tension and/or analgesia is still deemed suboptimal with extra lidocaine in SED-EA of after a SA, conversion to GA will be accomplished using propofol, remifentanil and a neuromuscular blocking agent. No IV opioids will be used. Anesthesia maintenance will be performed with TIVA. Rate of conversion to GA will be recorded by research personnel. Day 0
Secondary Total dose of the sedation Propofol sedation will be adjusted to keep a BIS index value in between 60 and 80. Day 0
Secondary Hemodynamic stability measured All hemodynamic parameters will be recorded by a computer hooked onto the anesthesia monitors. A mean arterial pressure (MAP) of 70 mmHg or higher will be kept with phenylephrine in 100 mcg increments (if heart rate (HR) of 50/minute and over) or ephedrine in 5 mg increments (if HR under 50). Total doses of vasopressors used will be recorded. Day 0
Secondary Time to return of motor and sensory function time to return of motor function is defined as the time when muscle strength in all three muscle groups tested is 5 of 5 on a 0 to 5 scale. The sensory dermatome level will be assessed using ice at the time of motor function return. Both assessments will begin 30 minutes after PACU arrival and continue every 30 minutes until motor function returns. Day 1
Secondary Post-operative nausea Post-operative nausea and vomiting (PONV), dizziness and confusion will be recorded by the PACU nurse using Aldrete scores. Day 1
Secondary PONV and anti-emetics PONV and anti-emetics in day care unit will be recorded. Day 1
Secondary Urinary retention Urinary retention, defined by the inability to urinate for 8 hours after surgery or the need for a placement of a straight catheter or foley, consistent with a previous study. Day 1
Secondary Opioid consumption Opioid consumption will be collected by the research team. Day 2
Secondary Length of stay Defined as the time frame from the end of the THA/TKA surgery to the time of the discharge order. Day 2
Secondary Failed discharded Defined as patient who is unable to be discharged within 24 hours after the end of surgery. Day 2
Secondary Complications related to the technique performed. Complications related to the technique performed. Day 3
Secondary Adverse event Adverse event Day 3
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04279054 - Decreased Neuraxial Morphine After Cesarean Delivery Early Phase 1
Active, not recruiting NCT04580030 - Tricuapid Annular Plane Sistolic Excursion Before General Anesthesia Can Predict Hypotension After Induction
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Recruiting NCT04099693 - A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP
Terminated NCT02481999 - Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Recruiting NCT05525104 - The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA op Het Herstel na Anesthesie Bij Kinderen). N/A
Recruiting NCT05024084 - Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth Phase 4
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03277872 - NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope N/A
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Terminated NCT02529696 - Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Terminated NCT03704285 - Development of pk/pd Model of Propofol in Patients With Severe Burns
Recruiting NCT05259787 - EP Intravenous Anesthesia in Hysteroscopy Phase 4
Completed NCT02894996 - Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient? N/A
Completed NCT05386082 - Anesthesia Core Quality Metrics Consensus Delphi Study
Terminated NCT03567928 - Laryngeal Mask in Upper Gastrointestinal Procedures N/A
Recruiting NCT06074471 - Motor Sparing Supraclavicular Block N/A
Completed NCT04163848 - CARbon Impact of aNesthesic Gas